HK1208222A1 - Modified release formulations for oprozomib - Google Patents
Modified release formulations for oprozomibInfo
- Publication number
- HK1208222A1 HK1208222A1 HK15108858.7A HK15108858A HK1208222A1 HK 1208222 A1 HK1208222 A1 HK 1208222A1 HK 15108858 A HK15108858 A HK 15108858A HK 1208222 A1 HK1208222 A1 HK 1208222A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- oprozomib
- release formulations
- modified release
- modified
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261717975P | 2012-10-24 | 2012-10-24 | |
US201261721244P | 2012-11-01 | 2012-11-01 | |
US201361793087P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/066679 WO2014066681A1 (fr) | 2012-10-24 | 2013-10-24 | Formulations à libération modifiée pour l'oprozomib |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1208222A1 true HK1208222A1 (en) | 2016-02-26 |
Family
ID=50485877
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15108858.7A HK1208222A1 (en) | 2012-10-24 | 2015-09-10 | Modified release formulations for oprozomib |
HK16103699.0A HK1215709A1 (zh) | 2012-10-24 | 2016-03-31 | 奧普佐米 的調節釋放製劑 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16103699.0A HK1215709A1 (zh) | 2012-10-24 | 2016-03-31 | 奧普佐米 的調節釋放製劑 |
Country Status (24)
Country | Link |
---|---|
US (2) | US9295708B2 (fr) |
EP (1) | EP2912025A4 (fr) |
JP (1) | JP6505604B2 (fr) |
KR (1) | KR20150070406A (fr) |
CN (1) | CN104968650A (fr) |
AP (1) | AP3681A (fr) |
AR (1) | AR093126A1 (fr) |
AU (1) | AU2013334258A1 (fr) |
BR (1) | BR112015008572A2 (fr) |
CA (1) | CA2888039A1 (fr) |
CL (1) | CL2015001085A1 (fr) |
CR (1) | CR20150266A (fr) |
EA (1) | EA201590797A1 (fr) |
HK (2) | HK1208222A1 (fr) |
IL (1) | IL238244A0 (fr) |
IN (1) | IN2015DN03921A (fr) |
MX (1) | MX2015005069A (fr) |
PE (1) | PE20151051A1 (fr) |
PH (1) | PH12015500823A1 (fr) |
SG (1) | SG11201502849XA (fr) |
TN (1) | TN2015000135A1 (fr) |
TW (1) | TW201422255A (fr) |
UY (1) | UY35091A (fr) |
WO (1) | WO2014066681A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
CA2988918A1 (fr) | 2015-06-19 | 2016-12-22 | Biotie Therapies, Inc. | Formulations de tozadenant a liberation controlee |
CN105949279A (zh) * | 2016-04-27 | 2016-09-21 | 浙江大学 | 蛋白酶体抑制剂Oprozomib及其类似物的制备方法 |
KR102571568B1 (ko) * | 2016-06-29 | 2023-08-25 | 케자르 라이프 사이언스 | 펩티드 에폭시케톤 면역프로테아제 저해제 및 그 전구체의 제조 방법 |
US20180078532A1 (en) | 2016-09-21 | 2018-03-22 | Amgen Inc. | Immediate release formulations for oprozomib |
WO2018112078A1 (fr) | 2016-12-14 | 2018-06-21 | Amgen Inc. | Formes pharmaceutiques à libération modifiée et à rétention gastrique pour oprozomib et leur procédé de fabrication |
BR112020005079A2 (pt) | 2017-09-14 | 2020-09-15 | Glaxosmithkline Intellectual Property Development Limited | tratamento de combinação para câncer |
CN110357940A (zh) * | 2019-08-02 | 2019-10-22 | 苏州艾和医药科技有限公司 | 奥普佐米合成工艺研究 |
WO2023220641A2 (fr) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Méthodes et utilisations associées à une thérapie par lymphocytes t et leur production |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
JPH06199657A (ja) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
WO1998010779A1 (fr) | 1996-09-13 | 1998-03-19 | New York University | Methode pour traiter des maladies parasitaires avec des inhibiteurs de proteasome |
JP4748839B2 (ja) * | 1999-03-25 | 2011-08-17 | 大塚製薬株式会社 | シロスタゾール製剤 |
HN2002000030A (es) * | 2001-02-12 | 2004-06-07 | Wyeth Corp | Nueva sal succinato de o-desmetil-venlafaxina |
US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
NZ595196A (en) * | 2005-11-09 | 2013-03-28 | Proteolix Inc | Peptide-based compounds for enzyme inhibition |
EP1974725A4 (fr) * | 2006-01-10 | 2012-12-05 | Kissei Pharmaceutical | Preparation a liberation prolongee et son procede de production |
WO2008140782A2 (fr) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Composés d'inhibition enzymatique |
SG10201902704TA (en) * | 2007-10-04 | 2019-04-29 | Onyx Therapeutics Inc | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
TWI504598B (zh) * | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
-
2013
- 2013-10-22 UY UY0001035091A patent/UY35091A/es not_active Application Discontinuation
- 2013-10-22 TW TW102138163A patent/TW201422255A/zh unknown
- 2013-10-24 JP JP2015539810A patent/JP6505604B2/ja not_active Expired - Fee Related
- 2013-10-24 AR ARP130103868A patent/AR093126A1/es unknown
- 2013-10-24 BR BR112015008572A patent/BR112015008572A2/pt not_active Application Discontinuation
- 2013-10-24 US US14/062,759 patent/US9295708B2/en not_active Expired - Fee Related
- 2013-10-24 EA EA201590797A patent/EA201590797A1/ru unknown
- 2013-10-24 AU AU2013334258A patent/AU2013334258A1/en not_active Abandoned
- 2013-10-24 SG SG11201502849XA patent/SG11201502849XA/en unknown
- 2013-10-24 EP EP13849834.0A patent/EP2912025A4/fr not_active Withdrawn
- 2013-10-24 CN CN201380067772.0A patent/CN104968650A/zh active Pending
- 2013-10-24 CA CA2888039A patent/CA2888039A1/fr not_active Abandoned
- 2013-10-24 MX MX2015005069A patent/MX2015005069A/es unknown
- 2013-10-24 WO PCT/US2013/066679 patent/WO2014066681A1/fr active Application Filing
- 2013-10-24 AP AP2015008387A patent/AP3681A/xx active
- 2013-10-24 PE PE2015000537A patent/PE20151051A1/es not_active Application Discontinuation
- 2013-10-24 KR KR1020157013739A patent/KR20150070406A/ko not_active Application Discontinuation
- 2013-10-24 IN IN3921DEN2015 patent/IN2015DN03921A/en unknown
-
2015
- 2015-04-08 TN TNP2015000135A patent/TN2015000135A1/fr unknown
- 2015-04-12 IL IL238244A patent/IL238244A0/en unknown
- 2015-04-15 PH PH12015500823A patent/PH12015500823A1/en unknown
- 2015-04-24 CL CL2015001085A patent/CL2015001085A1/es unknown
- 2015-05-20 CR CR20150266A patent/CR20150266A/es unknown
- 2015-09-10 HK HK15108858.7A patent/HK1208222A1/xx unknown
-
2016
- 2016-01-28 US US15/008,634 patent/US20160213610A1/en not_active Abandoned
- 2016-03-31 HK HK16103699.0A patent/HK1215709A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TN2015000135A1 (en) | 2016-10-03 |
SG11201502849XA (en) | 2015-05-28 |
BR112015008572A2 (pt) | 2017-07-04 |
UY35091A (es) | 2014-05-30 |
JP6505604B2 (ja) | 2019-04-24 |
US20160213610A1 (en) | 2016-07-28 |
AR093126A1 (es) | 2015-05-20 |
AP3681A (en) | 2016-04-19 |
AU2013334258A1 (en) | 2015-04-30 |
IL238244A0 (en) | 2015-06-30 |
MX2015005069A (es) | 2015-07-17 |
US20140113855A1 (en) | 2014-04-24 |
PE20151051A1 (es) | 2015-08-03 |
AP2015008387A0 (en) | 2015-04-30 |
CR20150266A (es) | 2015-08-14 |
JP2015535255A (ja) | 2015-12-10 |
EA201590797A1 (ru) | 2016-02-29 |
CN104968650A (zh) | 2015-10-07 |
KR20150070406A (ko) | 2015-06-24 |
TW201422255A (zh) | 2014-06-16 |
IN2015DN03921A (fr) | 2015-10-02 |
PH12015500823A1 (en) | 2015-06-22 |
EP2912025A1 (fr) | 2015-09-02 |
US9295708B2 (en) | 2016-03-29 |
EP2912025A4 (fr) | 2016-06-08 |
WO2014066681A1 (fr) | 2014-05-01 |
CL2015001085A1 (es) | 2015-08-28 |
HK1215709A1 (zh) | 2016-09-09 |
CA2888039A1 (fr) | 2014-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1255929A1 (zh) | 前體脂質體睾酮製劑 | |
ZA201500212B (en) | Progesterone formulations | |
IL234256B (en) | Tamper resistant immediate release formulations | |
HK1213779A1 (zh) | 用於立即和延長釋放的組合物 | |
HK1204973A1 (en) | Diclofenac formulations | |
ZA201202474B (en) | Controlled release compositions | |
HK1215709A1 (zh) | 奧普佐米 的調節釋放製劑 | |
HK1208173A1 (en) | Bromocriptine formulations | |
PL2908835T3 (pl) | Stabilne formulacje | |
GB201210530D0 (en) | Extended release formulations | |
EP2840704A4 (fr) | Ralentisseur | |
GB201110278D0 (en) | Formulations | |
GB201206178D0 (en) | Formulations | |
IL220200A (en) | Release device | |
HUP1100207A2 (en) | Modified release composition | |
GB201111013D0 (en) | Formulations | |
GB201107626D0 (en) | Formulations | |
GB201107627D0 (en) | Formulations | |
GB201105410D0 (en) | Formulations | |
GB201105360D0 (en) | Formulations | |
GB201104049D0 (en) | Formulations | |
GB201104048D0 (en) | Formulations | |
GB201102795D0 (en) | Formulations |